FORTHCOMING DEADLINE: J&W Announces Class Action Suit against Teva Pharmaceutical Industries Limited; Investors Encouraged to Contact Firm
SAN DIEGO- PRNewswire —September 2, 2017
Johnson & Weaver, LLP reminds investors that a class action case was filed against Teva Pharmaceutical Industries Limited (NYSE: TEVA) (“TEVA”) for purchasers of the stock between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”).
The complaint alleges that during the Class Period, defendants made false and/or misleading statements and failed to disclose that the poor performance of Teva’s U.S. generics business resulted in Teva’s recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this news was disclosed, shares of Teva declined significantly, which, according to the lawsuit, caused investors harm.
If you purchased shares during the Class Period and suffered a loss in Teva, you have until October 23, 2017, to request that the Court appoint you as lead plaintiff.
If you are interested in learning more about your legal rights and remedies or becoming a lead plaintiff in this case, please contact analyst Jim Baker (email@example.com) at 619-814-4471. If you email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.